Exenatide improves glucocorticoid-induced glucose intolerance in mice

Diabetes, Metabolic Syndrome and Obesity

Volumn 4, Issue , 2011, Pages 61-65

  Zhao, Ruiying ^a,b   Fuentes Mattei, Enrique ^a,b   Velazquez Torres, Guermarie ^a,b   Su, Chun Hui ^a,b   Chen, Jian ^a   Lee, Mong Hong ^a,b   Yeung, Sai Ching Jim ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Dexamethasone; Exenatide; Glucocorticoid; Insulin resistance; Mouse model

Indexed keywords

DEXAMETHASONE; EXENDIN 4; GLUCOSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG RESPONSE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; INSULIN RESISTANCE; INSULIN TOLERANCE TEST; MALE; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; SINGLE DRUG DOSE;

EID: 79953116091     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/DMSO.S15510     Document Type: Article

References (10)

1. Van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest. 2009;39:81-93.
2. Weiser MA, Cabanillas ME, Konopleva M, et al. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexatecytarabine regimen. Cancer. 2004;100:1179-1185.
3. Hoogwerf B, Danese RD. Drug selection and the management of corticosteroid-related diabetes mellitus. Rheum Dis Clin North Am. 1999;25:489-505.
4. Willi SM, Kennedy A, Brant BP, Wallace P, Rogers NL, Garvey WT. Effective use of thiazolidinediones for the treatment of glucocorticoidinduced diabetes. Diabetes Res Clin Pract. 2002;58:87-96.
5. Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract. 2009;15:469-474.
6. Feng YH, Velazquez-Torres G, Gully C, Chen J, Lee MH, Yeung SC. The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. J Cell Mol Med. 2010 May 3. [Epub ahead of print].
7. Linnebjerg H, Park S, Kothare PA, et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept. 2008;151(1-3):123-129.
8. Ranta F, Avram D, Berchtold S, et al. Dexamethasone induces cell death in insulin-secreting cells, an effect reversed by exendin-4. Diabetes. 2006;55:1380-1390.
9. Hansen KB, Vilsboll T, Bagger JI, Holst JJ, Knop FK. Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects. J Clin Endocrinol Metab. 2010;95:3309-3317.
10. Van Raalte DH, van Genugten RE, Linssen MML, Ouwens MDM, Diamant M. The glucagon-like peptide receptor agonist exenatide protects against glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. Diabetes. 2010;59(Suppl 1):A62.